Multiple treatment lines and prognosis in metastatic colorectal cancer patients
The proportion of patients with metastatic colorectal cancer (mCRC) receiving second or further lines of treatment has not been widely studied. To shed light on this issue, we retrospectively analysed the treatments administered for metastatic disease, and investigated prognostic factors after a diagnosis of metastases, in a consecutive cohort of mCRC patients. Three hundred forty-six mCRC patients were enrolled: 173 were stage II or III (metachronous group), and 173 stage IV (synchronous group) at diagnosis. Survival was calculated between the date of metastatic disease and the date of death or last follow-up. Patients with synchronous lesions more frequently had multiple disease sites, peritoneal carcinomatosis and massive liver deposits, whereas significantly more patients with metachronous lesions developed lung metastases as the sole disease site. 97.4% patients received at least one, 62.4% two, 41.9% three and 23.7% four treatment lines. Patients with metachronous metastases more frequently underwent surgery of metastases in first-line treatment (48.5 versus 24.8%), and more of them were progression-free at the time of the analysis (44 versus 34.9%). At univariate analysis, age > 70 years, multiple disease sites and peritoneal carcinomatosis were associated with significantly decreased survival, whereas surgery of metastases and isolated lung metastases predicted better survival. At multivariate analysis, only peritoneal carcinomatosis and surgery of metastases independently affected survival. The percentage of patients who received an active treatment decreased going from first- to fourth-line treatment. However, the proportion of patients who received efficacious treatment in advanced line remained high. Surgery of metastases was the most important prognostic factors.
KeywordsMetastatic colorectal cancer Multiple treatment lines Prognostic factors Continuum of care
We thank Jean Ann Gilder (Scientific Communication srl., Naples, Italy) for text editing and linguistic revision.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics 2012. CA: a Cancer Journal for Clinicians, 65(2), 87–108.Google Scholar
- 2.Coviello, V., Buzzoni, C., Fusco, M., et al for the AIRTUM Working Group.(2017). Survival of cancer patients in Italy. Epidemiol Prev, 41(2 Suppl 1), 1–244.Google Scholar
- 3.Gao, P., Song, Y. X., Wang, Z. N., Xu, Y. Y., Tong, L. L., Sun, J. X., Yu, M., & Xu, H. M. (2013). Is the prediction of prognosis not improved by the seventh edition of the TNM classification for colorectal cancer? Analysis of the surveillance, epidemiology, and end results (SEER) database. BMC Cancer, 13, 123.CrossRefGoogle Scholar
- 7.André, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Bridgewater, J., Rivera, F., & de Gramont, A. (2009). Improved overall survival with Oxaliplatin, Fluorouracil and Leucovorin as adjuvant treatment for stage II or III colon cancer in the MOSAIC trial. Journal of Clinical Oncology, 27(19), 3109–3116.CrossRefGoogle Scholar
- 8.Figueredo, A., Coombes, M. E., & Mukherjee, S. (2008). Adjuvant therapy for completely resected stage II colon Cancer (review). Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD005390.pub2.
- 9.Kapiteijn E., Marijnen C.A.M., Nagtegaal I.D. et al for the Dutch Colorectal Cancer Group.(2001). Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. The New England Journal of Medicine, 345(9), 638–646.Google Scholar
- 10.Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., Karstens, J. H., Liersch, T., Schmidberger, H., Raab, R., & German Rectal Cancer Study Group. (2004). Preoperative versus postoperative chemoradiotherapy for rectal cancer. The New England Journal of Medicine, 351(17), 1731–1740.CrossRefGoogle Scholar
- 11.Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., & Kabbinavar, F. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorinfor metastatic colorectal cancer. The New England Journal of Medicine, 350(23), 2335–2342.CrossRefGoogle Scholar
- 13.Van Cutsem, E., Köhne, C. H., Láng, I., et al. (2011). Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology, 29(15), 2011–2019.CrossRefGoogle Scholar
- 15.Van Cutsem, E., Tabernero, J., Lakomy, R., et al. (2012). Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with oxaliplatin-based regimen. Journal of Clinical Oncology, 30(28), 2499–2506.Google Scholar
- 19.Adam, R., Wicherts, D. A., de Haas, R. J., Ciacio, O., Lévi, F., Paule, B., Ducreux, M., Azoulay, D., Bismuth, H., & Castaing, D. (2009). Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? Journal of Clinical Oncology, 27(11), 1829–1835.CrossRefGoogle Scholar
- 20.Grothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H. J. (2004). Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. Journal of Clinical Oncology, 22(7), 1209–1214.CrossRefGoogle Scholar
- 21.Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., Landi, B., Colin, P., Louvet, C., & de Gramont, A. (2004). FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of Clinical Oncology, 22(2), 229–237.CrossRefGoogle Scholar
- 24.Hess, G. P., Wang, P. F., Quach, D., Barber, B., & Zhao, Z. (2010). Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. Journal of Oncology Practice/ American Society of Clinical Oncology, 6(6), 301–307.CrossRefGoogle Scholar
- 26.Tampellini, M., Di Maio, M., Baratelli, C., et al. (2017). Treatment of patients with metastatic colorectal cancer in a real-world scenario: probability of receiving second and further lines of therapy and description of clinical benefit. Clinical Colorectal Cancer, 16(4), 372–376.CrossRefGoogle Scholar
- 27.Schwartzberg, L. S., Rivera, F., Karthaus, M., et al. (2017). A randomized, multicenter phase II study of Panitumumab plus modified fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, Unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. Journal of Clinical Oncology, 32(21), 2240–2247.CrossRefGoogle Scholar
- 28.Modest, D. P., Stintzing, S., Fischer von Weikersthal, L., et al. (2015). Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. Journal of Clinical Oncology, 33(32), 718–723.CrossRefGoogle Scholar
- 29.Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., Tonini, G., Carlomagno, C., Allegrini, G., Chiara, S., D’Amico, M., Granetto, C., Cazzaniga, M., Boni, L., Fontanini, G., & Falcone, A. (2015). FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. The Lancet Oncology, 16(13), 1306–1315.CrossRefGoogle Scholar